Exelixis, Inc.

Equities

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
23.7 ^USD	+0.72%		+5.24%	-1.21%

Apr. 12	North American Morning Briefing : Big Banks Kick -2-	DJ
Apr. 11	Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25	MT

Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on March 20, 2023.

January 08, 2024 at 09:06 am EST

From September 30, 2023 to December 29, 2023, the company has repurchased 9,287,000 shares, representing 2.99% for $208.42 million. With this, the company has completed the repurchase of 26,230,000 shares, representing 8.25% for $550 million under the buyback announced on March 20, 2023.

Latest news about Exelixis, Inc.

North American Morning Briefing : Big Banks Kick -2-	Apr. 12	DJ
Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25	Apr. 11	MT
Jacqueline Wright Notifies Exelixis, Inc. of Her Decision Not to Stand for Re-Election to the Board of Directors	Mar. 29	CI
Transcript : Exelixis, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:45 AM	Mar. 13
Transcript : Exelixis, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 09:20 AM	Mar. 12
Transcript : Exelixis, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM	Mar. 05
Exelixis Insider Bought Shares Worth $3,932,734, According to a Recent SEC Filing	Feb. 22	MT
Transcript : Exelixis, Inc. Presents at Oppenheimer 34th Annual Healthcare Life Sciences Conference, Feb-13-2024 12:40 PM	Feb. 13
Transcript : Exelixis, Inc. Presents at Guggenheim Healthcare Talks\| 6th Annual Biotechnology Conference, Feb-08-2024 09:00 AM	Feb. 08
RBC Raises Price Target on Exelixis to $28 From $26, Keeps Outperform Rating	Feb. 07	MT
Exelixis Swings to Earnings in Fiscal Q4 as Sales Increase; 2024 Revenue Guidance Set	Feb. 06	MT
Transcript : Exelixis, Inc., Q4 2023 Earnings Call, Feb 06, 2024	Feb. 06
Exelixis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 06	CI
Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024	Feb. 06	CI
Earnings Flash (EXEL) EXELIXIS Reports Q4 Revenue $480M, vs. Street Est of $477.9M	Feb. 06	MT
Earnings Flash (EXEL) EXELIXIS Posts Q4 EPS $0.33, vs. Street Est of $0.31	Feb. 06	MT
Exelixis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 06	CI
Barclays Adjusts Price Target on Exelixis to $25 From $24, Keeps Overweight Rating	Jan. 30	MT
Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024	Jan. 25	CI
Bristol-Myers Squibb, Exelixis Say Opdivo Plus Cabometyx Continue to Show Benefits in Kidney Cancer Trial	Jan. 22	MT
Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)	Jan. 22	CI
Transcript : Exelixis, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 04:30 PM	Jan. 08
Exelixis Sees Fiscal 2023 Revenue at Lower End of Guidance; Issues Fiscal 2024 Revenue Outlook	Jan. 08	MT
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on March 20, 2023.	Jan. 08	CI
Exelixis, Inc. announces an Equity Buyback for $450 million worth of its shares.	Jan. 08	CI

Chart Exelixis, Inc.

Duration

Period

More charts

Company Profile

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Exelixis, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

23.7 USD

Average target price

26.63 USD

Spread / Average Target

+12.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
EXELIXIS, INC.	-1.21%	6.99B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs